stockrow
Saturday 7 November 2026
Export IBO’s income statement to Excel — free account
Impact Biomedical Inc.
Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022.
- Revenue
- −57.1%
- EPS
- +99.5%
- Free cash flow
- +167.7%
Quarter to June 2026, against a year earlier
4.10
0.30
−6.82%
Follow IBO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | — | — | 0 | 0 | (13.8%) | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | 100.00 | — | — | (1,225.00) | (1,111.43) | (1,325.0) pt | ||||||
| EBT | — | — | — | — | — | — | (8) | (4) | (25) | (14) | (2) | +22.4% | ||||||
| EBT margin, % | — | — | — | — | — | — | (15,752.00) | 0.00 | 0.00 | (45,156.25) | (5,154.29) | (29,404.2) pt | ||||||
| Net income | — | — | — | — | — | — | (7) | (4) | (25) | (12) | 1 | +17.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | +12.5% | |||||
| Earnings | — | — | — | — | — | — | (1.30) | (0.92) | (29.04) | (4.80) | (1.11) | +54.6% | ||||||
| Cash flow | — | — | — | — | — | — | (0.40) | (0.60) | (3.35) | (0.76) | (0.06) | +23.5% | ||||||
| Capex | — | — | — | — | — | — | (0.05) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | (0.45) | (0.60) | (3.35) | (0.76) | (0.06) | +18.8% | ||||||
| Book value | — | — | — | — | — | — | 5.85 | 5.92 | 8.49 | 6.22 | 1.64 | +2.1% | ||||||
| Shares, m | — | — | — | — | — | — | 6 | 5 | 1 | 3 | 6 | (23.5%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | — | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | — | — | 552.57 | 1,000.83 | 276.3 | ||||||
| P/B | — | — | — | — | — | — | 1.02 | — | — | 2.91 | 2.50 | 2.0 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | — | 649.74 | 1,228.29 | 324.9 | ||||||
| EV/FCF | — | — | — | — | — | — | (13.50) | — | — | (27.92) | (81.73) | (20.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (2) | (3) | (3) | (2) | (1) | (5.5%) | |||||
| Capex | — | — | — | — | — | — | 0 | 0 | — | — | 0 | (93.5%) | ||||||
| Free cash flow | — | — | — | — | — | — | (3) | (3) | (3) | (2) | (1) | (9.1%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (10) | (13) | (7) | (1) | (2) | (58.5%) | |||||
| Net debt | — | — | — | — | — | — | 0 | 0 | (2) | 0 | 0 | +14.5% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | 33 | 28 | 7 | 16 | 14 | (21.9%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (9.52) | (76.11) | (62.81) | 4.41 | (62.8) pt | |||||
| ROIC | — | — | — | — | — | — | (6.51) | (8.91) | (343.08) | (17.21) | (22.81) | (10.7) pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | (14.25) | (139.68) | (104.15) | 24.01 | (104.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 5 | 8 | 8 | — | +26.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Impact Biomedical Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HYPD Hyperion DeFi, Inc. | $39.8M | — (loss-making) | 0.5× | +2,333.33% (above 0%: growing) | n/m | +86.82% (above 0%: growing) | 100.00% | 8,668.63% | Compare |
| DWTX Dogwood Therapeutics, Inc | $39.8M | — (loss-making) | — | — | n/m | +10.31% (above 0%: growing) | — | 0.00% | Compare |
| EXOZ eXoZymes Inc. | $38.1M | — (loss-making) | — | — | n/m | −3.25% (below 0%: shrinking) | — | 0.00% | Compare |
| IBO Impact Biomedical Inc. | $38.0M | — (loss-making) | — | −57.14% (below 0%: shrinking) | n/m | +167.72% (above 0%: growing) | 66.67% | (23,400.00%) | |
| ELTX Elicio Therapeutics, Inc. | $37.9M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRCE Grace Therapeutics, Inc. | $37.5M | — (loss-making) | — (loss-making) | +5,127.27% (above 0%: growing) | n/m | −78.85% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALDX Aldeyra Therapeutics, Inc. | $37.2M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TVGN Tevogen Inc. | $36.2M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| Median of peers | $37.7M | — | — | +2,333.33% | — | +7.28% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 22 September 2025
Ownership
Directors and executive officers, together
less than 1%
DSS, Inc.
100.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement